Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Triveni Bio Doses First Patient in Global Phase 2 Proof-of-Concept Study of TRIV-573 in Atopic ...

Summary by Hastings Tribune
TRIV-573, potential first-in-class KLK5/7 x IL-13 bispecific, simultaneously targets skin barrier dysfunction and inflammation to address fundamental drivers of disease

1 Articles

Hastings TribuneHastings Tribune
Center

Triveni Bio Doses First Patient in Global Phase 2 Proof-of-Concept Study of TRIV-573 in Atopic ...

TRIV-573, potential first-in-class KLK5/7 x IL-13 bispecific, simultaneously targets skin barrier dysfunction and inflammation to address fundamental drivers of disease

·Nebraska, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in Nebraska, United States on Tuesday, October 13, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Hastings, Nebraska icon

Hastings, Nebraska

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal